Higher doses of fluoxetine may have proven more effective and a more robust comparison of duloxetine, and fluoxetine should include a broader and more optimal dose range for comparison.
the combination of the use of a 3D T1-weighted and a high resolution T2*weighted sequence; a more optimal contrast dose; the use of the 'obturatur' (= semi-sagittal) planes for evaluation; and special care in using the MR-findings to locate small metastatic nodes during surgery.
Possible explanations for these better results compared with earlier studies[ 4] are: the combination of the use of a 3D T1-weighted and a high resolution T2*weighted sequence; a more optimal contrast dose; the use of the 'obturatur' (= semi-sagittal) planes for evaluation; and special care in using the MR-findings to locate small metastatic nodes during surgery.
More importantly, optimal dose-scheduling allows dose reduction in sunitinib by at least 50% while maintaining the same antitumor effect.
More double-blinded RCTs are required to elaborate more on (1) optimal dose of BTX-A, (2) optimal duration of treatment, and (3) optimal route of administration.
The increasing database of biomarker information in CIT may provide the foundation for the next generation of CIT models, including those that are more amenable to questions of optimal dosing duration.
These reports suggest that measuring EGFR in patient tissue may indeed correlate to therapeutic outcome, yet it is clear that application of alternative, robust, reproducible, and scalable technologies for conclusive objective quantitation of the EGFR protein is required to predict and improve therapeutic outcomes through more optimal patient selection, monitoring, and dosing.
They demonstrated that patients who received 85% or more of the optimal dose of CMF had a longer relapse free and OS.
When compared with different up-and-down schemes, including '3+3' designs, EWOC assigns fewer patients to either subtherapeutic or toxic dose levels, treats more patients at optimal dose levels and estimates the MTD with smaller average bias and mean squared error (Babb et al, 1998).
Pre-transplant genotyping of these sequence variants may help to identify renal transplant recipients at risk of CNI over- or underexposure, and contribute to reducing CNI-related adverse events by more optimal determination of individual starting doses.
